Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

  1. Saura, C.
  2. Hlauschek, D.
  3. Oliveira, M.
  4. Zardavas, D.
  5. Jallitsch-Halper, A.
  6. de la Peña, L.
  7. Nuciforo, P.
  8. Ballestrero, A.
  9. Dubsky, P.
  10. Lombard, J.M.
  11. Vuylsteke, P.
  12. Castaneda, C.A.
  13. Colleoni, M.
  14. Santos Borges, G.
  15. Ciruelos, E.
  16. Fornier, M.
  17. Boer, K.
  18. Bardia, A.
  19. Wilson, T.R.
  20. Stout, T.J.
  21. Hsu, J.Y.
  22. Shi, Y.
  23. Piccart, M.
  24. Gnant, M.
  25. Baselga, J.
  26. de Azambuja, E.
  27. Montrer des auteurs +
Revue:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Année de publication: 2019

Volumen: 20

Número: 9

Pages: 1226-1238

Type: Article

DOI: 10.1016/S1470-2045(19)30334-1 GOOGLE SCHOLAR